MDT Stock Price Today (October 2026) — Medtronic plc Analysis & Key Metrics 2026-10-07
Medtronic plc (MDT) is trading at $85.51, down 1.81% today (as of October 2026). The stock continues to show mixed signals with a short-term dip within a broader uptrend, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $104.83 (22.6% upside).
- Volatility is low (16.47% annualized), implying relatively contained price movements for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (9.90% YoY) alongside competitive pressures in the Medical Devices space.
MDT Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
Medtronic plc - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $128.71B
P/E Ratio
Forward P/E: 14.15
Revenue Growth
Year over Year
Analyst Target
+22.6% upside potential
Key Investor Questions About MDT
What investors need to know before buying
Based on current market data, MDT presents a neutral technical setup with looking solid fundamentals.
- Technicals say: Neutral (RSI 34.13)
- Fundamentals say: Looking solid (debt and growth supportive)
MDT's growth trajectory depends on its ability to expand within the Medical Devices sector while managing margin pressures.
- Future growth will depend on performance in core Medical Devices operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for MDT investors include debt exposure and competitive dynamics in the Medical Devices industry.
- $29.15B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Medical Devices.
52-Week Trading Range
Over the past year, MDT stock traded between $73.31 and $106.33 and currently trades in the middle of that range. Big swings are less likely unless a major catalyst emerges.
Volatility & Risk Profile
With 16.47% annualized volatility and β=0.29, the stock exhibits low sensitivity to market moves—making MDT suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional ownership with low short interest suggests steadier hands and low immediate risk.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Medtronic PLC's Dividend Analysis
Medtronic PLC (NYSE:MDT) recently announced a total dividend of $0.72 per share with the ex-dividend date set for 2026-09-25, including $0.72 per share cash dividend payable on 2026-10-16. As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates. Using the data from GuruFocus, let's look into Medtronic PLC's dividend performance and assess its sustainability.
Could Medtronic (MDT)’s $700 Million Robotics Bet Unlock its Next Growth Engine?
On September 1, Medtronic plc (NYSE:MDT) announced a $700 million strategic partnership with Hong Kong-based Cornerstone Robotics, securing rights to distribute Cornerstone’s Sentire surgical system in select market-approved regions outside the U.S. Medtronic will co-distribute Sentire alongside its proprietary Hugo robotic-assisted surgery system across Europe, China, and Singapore. The move allows Medtronic to offer tiered […]
Here's Why Medtronic (MDT) Fell More Than Broader Market
Medtronic (MDT) reached $89.3 at the closing of the latest trading day, reflecting a -1.62% change compared to its last close.
Medtronic (MDT): Q1 Beat Sparks Target Hikes, but Wall Street Splits on Re-Rating Case
Medtronic plc (NYSE:MDT) drew a broad round of price-target increases after its fiscal 2027 first-quarter results, but Wall Street remains divided over whether accelerating growth can support a meaningful re-rating of the stock. The acceleration follows an earlier debate over whether Medtronic (MDT) is finally becoming a turnaround story. Bull Case: Growth Is Broadening Mizuho […]
Jim Cramer Called Medtronic a "Quandary." Here's Why He's Exactly Right.
Wall Street doesn't appear to be giving Medtronic credit for its improving results.
What Does Medtronic (MDT) FDA Clearance Mean For Its Hugo Surgery Push?
Medtronic (NYSE:MDT) received FDA clearance for its LigaSure vessel-sealing device on the Hugo robotic surgery system in the U.S. The authorization allows LigaSure to be used on the Hugo platform for soft-tissue procedures in U.S. hospitals and surgical centers. The cleared configuration integrates a widely used vessel-sealing tool with Medtronic’s robotic-assisted surgery platform for general surgery use. The new FDA clearance for LigaSure on Hugo is one more factor to weigh alongside the...
Should You Buy Medtronic Stock as Its Hugo Surgical Robot Gains Ground?
The company is in the process of expanding the uses for its Hugo Surgical System and expanding its revenue base.
Why BSX Stock Lost More Than Half Its Value While Sales Kept Rising
Boston Scientific (BSX) has fallen about 54% since late December 2025, and it now sits at $43.91, just above a 52-week low of $42.63. Device peers were mixed over the same nine months: Abbott lost about 17%, Medtronic barely moved, and Johnson & Johnson rose about 32%. The market repriced Boston Scientific's growth rate after management concentrated its guidance cut in two core product lines.
Medtronic (MDT) Raises its Outlook Again as Heart Device Demand Keeps Climbing
Reuters reported that Medtronic plc (NYSE:MDT) raised the lower end of its fiscal 2027 profit forecast and its revenue growth outlook on September 1, banking on strong demand for heart devices used in complex cardiovascular procedures. The Ireland-based company raised the lower end of its adjusted per-share profit forecast to $5.94 from $5.90, keeping the […]
BSX vs. MDT: Which Electrophysiology Stock Is the Better Bet Now?
Boston Scientific faces near-term pressure in electrophysiology, while Medtronic gains share and sees stronger momentum across key franchises.
Explore More Analysis for MDT
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Nov 16, 2026 (before the open, usually)
Frequently Asked Questions
Common investor questions about Medtronic plc
Medtronic plc (MDT) is currently trading at $85.51. The RSI (14-day) is at 34.1, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $104.83 implies 22.6% upside from current levels. Volatility is low at 16.5% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Medtronic plc (MDT): The trailing P/E ratio is 25.15, which is in line with broader market averages. The forward P/E is 14.15, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 1.78, near 1.0, suggesting roughly fair value relative to growth. Price-to-Book is 2.43. Price-to-Sales is 3.30. Valuation should be compared to Medical Devices industry peers for context, as different sectors trade at different multiples.
Based on 24 analysts covering MDT, the consensus price target is $104.83. This represents a 22.6% upside from the current price of $85.51. The range spans from a low target of $85.00 to a high target of $121.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Medtronic plc (MDT) pays a dividend with a current yield of approximately 3.37%. The annualized dividend rate is $2.85 per share. The payout ratio is 70.2%, which is moderate and suggests adequate earnings coverage for the dividend. The most recent ex-dividend date was Sep 25, 2026.
Key risks for Medtronic plc (MDT) investors include: 1. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 2. Medical Devices sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Medtronic plc's (MDT) current debt and financial health profile: Total debt stands at $29.15B. The debt-to-equity ratio is 0.58x, which is moderate and generally manageable for most companies. The current ratio is 2.13, indicating strong short-term liquidity. The quick ratio is 1.36. The company holds $9.22B in cash and equivalents. Free cash flow is positive at $4.63B, providing a cushion for debt servicing and shareholder returns.